Related Experiment Videos
Salbutamol in cardiogenic shock complicating acute myocardial infarction
Insights
Intravenous salbutamol improved hemodynamics in patients with cardiogenic shock after myocardial infarction. This beta-agonist may aid treatment for heart attack complications, offering a potential survival benefit.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Cardiogenic shock is a life-threatening complication of acute myocardial infarction.
- Effective treatments for cardiogenic shock remain limited, necessitating exploration of novel therapeutic agents.
Purpose of the Study:
- To evaluate the efficacy and hemodynamic effects of intravenous salbutamol in patients experiencing cardiogenic shock secondary to acute myocardial infarction.
- To assess the potential role of salbutamol in improving outcomes for patients with acute myocardial infarction and pump failure.
Main Methods:
- A cohort of 31 patients with cardiogenic shock complicating acute myocardial infarction received intravenous salbutamol at a dose of 13 microgram/min.
- Hemodynamic parameters, including cardiac index, systemic vascular resistance, heart rate, and pulmonary artery end-diastolic pressure, were monitored in nine patients.
Main Results:
- Intravenous salbutamol significantly increased cardiac index by 41% and decreased systemic vascular resistance by 16%.
- Heart rate increased by 13%, while pulmonary artery end-diastolic pressure decreased.
- Overall survival to hospital discharge was 27% (8 out of 31 patients).
Conclusions:
- Salbutamol demonstrated beneficial hemodynamic effects, including increased cardiac output and reduced afterload, in patients with cardiogenic shock post-myocardial infarction.
- Clinical improvement in survivors was attributed to either the positive chronotropic effects or afterload reduction mediated by salbutamol.
- Intravenous salbutamol shows promise as a therapeutic option for managing cardiogenic shock and pump failure in the context of acute myocardial infarction.
Abstract:
Intravenous salbutamol (13 microgram/min) has been given to 31 patients with cardiogenic shock complicating acute myocardial infarction. Haemodynamic measurements were made in nine of these patients. Salbutamol increased cardiac index by 41 per cent from 1.25 +/- 0.06 l/min per m2 to 1.76 +/- 0.19 l/min per m2 and decreased systemic vascular resistance by 16 per cent from 26.2 +/- 1.9 units to 21.9 +/- 2.1 units. Heart rate rose by 13 per cent from 95 +/- 4.5 beats/min to 106 +/- 6.0 beats/min. Pulmonary artery end-diastolic pressure fell from 20.6 +/- 1.7 mmHg to 16.9+/- 1.9 mmHg. Of the 31 patients, eight survived to leave hospital (27%). Five of the survivors had initial low heart rates and in these patients the clinical improvement was probably attributable to the positive chronotropic action of salbutamol. In the remaining three survivors clinical improvement was probably a result of salbutamol mediated afterload reduction. Salbutamol may be useful in the treatment of cardiogenic shock and pump failure complicating acute myocardial infarction.